# Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer

> **NCT02413853** · PHASE2 · WITHDRAWN · sponsor: **University of Southern California**

## Conditions studied

- Colorectal Adenocarcinoma
- Stage IVA Colorectal Cancer
- Stage IVB Colorectal Cancer

## Interventions

- **DRUG:** CBP/beta-catenin Antagonist PRI-724
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Leucovorin Calcium
- **DRUG:** Oxaliplatin
- **DRUG:** Fluorouracil
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02413853
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-11
- **Primary completion:** 2017-11
- **Final completion:** 2018-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study drug supply issues
- **Last updated:** 2017-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413853, "Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02413853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*